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Abstract
Background: Despite the important roles of vascular smooth muscle cells and endothelial cells in atherosclerotic
lesion formation, data regarding the associations of functional polymorphisms in the genes encoding growth
factors with the severity of coronary artery disease (CAD) are lacking. The aim of the present study is to analyze the
relationships between functional polymorphisms in genes encoding basic fibroblast growth factor (bFGF, FGF2),
epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), platelet derived growth factor-B (PDGFB),
transforming growth factor-β1 (TGF-β1) and vascular endothelial growth factor A (VEGF-A) and the severity of
coronary atherosclerosis in patients with stable CAD undergoing their first coronary angiography.
Methods: In total, 319 patients with stable CAD who underwent their first coronary angiography at the Silesian
Centre for Heart Diseases in Zabrze, Poland were included in the analysis. CAD burden was assessed using the
Gensini score. The TaqMan method was used for genotyping of selected functional polymorphisms in the FGF2,
PDGFB, TGFB1, IGF1 and VEGFA genes, while rs4444903 in the EGF gene was genotyped using the polymerase chain
reaction-restriction fragment length polymorphism (PCR-RFLP) method. The associations between the selected
polymorphisms and the Gensini were calculated both for the whole cohort and for a subgroup of patients without
previous myocardial infarction (MI).
Results: There were no differences in the distribution of the Gensini score between the genotypes of the analyzed
polymorphisms in FGF2, EGF, IGF1, PDFGB, and TGFB1 in the whole cohort and in the subgroup of patients without
previous MI. The Gensini score for VEGFA rs699947 single-nucleotide polymorphism (SNP) in patients without
previous myocardial infarction, after correction for multiple testing, was highest in patients with the A/A genotype,
lower in heterozygotes and lowest in patients with the C/C genotype, (p value for trend = 0.013, false discovery rate
(FDR) = 0.02). After adjustment for clinical variables, and correction for multiple comparisons the association
between the VEGFA genotype and Gensini score remained only nominally significant (p = 0.04, FDR = 0.19) under
the dominant genetic model in patients without previous MI.
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Conclusions: We were unable to find strong association between analyzed polymorphisms in growth factors and
the severity of coronary artery disease, although there was a trend toward association between rs699947 and the
severity of CAD in patients without previous MI.
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Background
Early atherosclerotic changes in coronary arteries are
characterized by proteoglycans, extracellular lipid accu-
mulation and a large number of vascular smooth muscle
cells (VSMCs) that migrate from the medial portion of
the artery into the endothelial layer [1]. At later stages,
changes may include an increase in collagen production,
which takes place within a lesion with a large number of
VSMCs, and a lesion may evolve into a thick cap
fibroatheroma [2]. However, depletion of smooth muscle
cells (SMCs) may also occur, along with a decrease in
collagen production and an increase in lipid accumula-
tion, leading to the creation of vulnerable plaque or a
thin cap fibroatheroma [3]. Thin cap fibroatheromas are
more susceptible to erosion/ruptures that lead to acute
coronary syndromes, whereas thick cap fibroatheromas
are mostly responsible for stable coronary artery disease
(CAD) symptoms [2, 3]. Despite the important role of
VSMCs in atherosclerotic lesion formation, thus far,
there have been no studies, with the exception of ana-
lyses regarding vascular endothelial growth factor A
(VEGF-A) [4] and transforming growth factor-β1 (TGF-
β1) [5], analyzing functional polymorphisms in genes
encoding growth factors that affect VSMCs in terms of
the severity of coronary atherosclerosis. The aim of the
present study is to analyze the relationships between
functional polymorphisms in genes encoding basic fibro-
blast growth factor (bFGF, FGF2), epidermal growth fac-
tor (EGF), insulin-like growth factor-1 (IGF-1), platelet
derived growth factor-B (PDGFB), TGF-β1 and VEGF-A
and the severity of CAD in patients with stable CAD
undergoing their first coronary angiography.
Methods
In total, 319 patients with stable CAD who underwent
their first coronary angiography at the Silesian Centre
for Heart Diseases in Zabrze, Poland, were enrolled. All
patients were subjected to implantation of at least one
bare metal stent. CAD burden was assessed using the
Gensini score, which is a derivative of the dominance of
the right or left coronary artery and of the degree of
stenosis [6]. The analysis of lesion severity was per-
formed with quantitative coronary angiography (QCA)
and the narrowing between 0–25 %, 25–50 %, 50–75 %,
75–90 %, 90–99 %, and 100 %; stenosis was scored as, 1,
2, 4, 8, 16, and 32 points, respectively [6]. Cardiologists
assessing coronary angiography records were blinded to
genotypic results, and researchers performing genotypic
analysis were blinded to angiographic results. Analyses
were performed in the whole cohort and in the subgroup
of patients without previous myocardial infarction (MI).
Genotyping
Genomic DNA from 200 μl of whole blood was ex-
tracted using the commercially available GeneMatrix
Quick Blood DNA Purification Kit (EURX, Poland) ac-
cording to the manufacturer’s instructions. The eluted
DNA was precipitated and dissolved. The aim was to
discriminate between two alleles of specific single-
nucleotide polymorphisms (SNPs) of FGF2 (rs308395),
EGF (rs4444903), IGF1 (rs35767), PDGFB (rs2285094),
TGFB1 (rs1800470) and VEGFA (rs699947).
Genotyping of the EGF gene using PCR-RFLP
The EGF gene was genotyped using the polymerase
chain reaction-restriction fragment length polymorphism
(PCR-RFLP) using the primers (nucleotide position −78
to +164) and methods with minor modification de-
scribed by Shahbazi et al. [7]. PCR reaction mixtures
with a final volume of 25 μl contained the following: 2 μl
of genomic DNA, 0.2 μl of 25 mM dNTP Mix (contain-
ing dATP, dCTP, dGTP, and dTTP), 1.2 μl of 10 μM
forward and reverse primers (Genomed, Poland), 2.5 μl
of DyNAzyme Buffer (Thermo Scientific, USA), 0.3 μl of
DyNAzyme II DNA Polymerase (2 U/μl; Thermo Scien-
tific, USA) and 17.6 μl of molecular grade water (Qiagen,
Germany). The PCR reaction was performed in a Mas-
tercycler personal thermocycler (Eppendorf, Germany),
and the conditions were 5 min of initial denaturation at
95 °C, followed by 35 cycles of denaturation at 95 °C for
45 s, annealing at 57 °C for 45 s, extension at 72 °C for
45 s and a final extension at 72 °C for 10 min. The
length of the amplified EGF fragment was 242 bp. The
PCR product was digested using AluI to type the EGF
61A/G polymorphism by RFLP analysis. The PCR prod-
uct was digested at 37 °C for 12 h in a Mastercycler per-
sonal thermocycler (Eppendorf, Germany) in a solution
containing 5 μl of PCR product, 1 μl of AluI restriction
enzyme (10 U/μl, Thermo Scientific, USA), 1 μl of 10×
Buffer Tango (ThermoScientific, USA), and 3 μl of mo-
lecular grade water (Qiagen, Germany) per reaction.
Then, AluI was inactivated by incubation at 65 °C for
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20 min. AluI cleaved the 242-bp PCR product into frag-
ments of 15, 34 and 193 bp for GG homozygotes and
15, 34, 91 and 102 bp for AA homozygotes.
Genotyping the FGF2, PDGFB, TGFB1 and VEGFAA genes
using the TaqMan assay
DNA samples were genotyped by employing the 5′ nu-
clease assay for allelic discrimination using TaqMan SNP
Genotyping Assays (Applied Biosystems, CA, USA). The
PCR reaction mixtures included 5 ng of genomic DNA
in a 25-μl reaction volume and the following concentra-
tions of other reagents: 2× TaqMan Genotyping Master
Mix (No AmpErase UNG), primers at 900 nM final con-
centration and 200 nM of each probe (Applied Biosys-
tems). Samples which have three different genotypes
were amplified and subjected to sequencing and, after
confirming the genotype, used as positive control sam-
ples. Sequence analysis of a polymorphic region of the
genes were performed by using BigDye® Terminator v3.1
Cycle Sequencing Kit (Applied Biosystems, Thermo
Fisher Scientific, USA). The reaction was carried out in
a capillary sequencer 3730xl DNA Analyzer. As negative
control DNase-, RNase-, and Protease - free Water (Qiagen,
Germany) was used. We were able to establish genotype of
rs1800470 (TGF-β1) for 316 (99.1 %) patients, whilst geno-
types of rs308395 (bFGF2), rs4444903 (EGF), rs35767
(IGF-1), PDGFB (rs2285094) and VEGF-A (rs699947) were
successfully established for all patients.
Reactions were performed in 96-well plates. Control
samples were run in parallel with unknown DNA samples.
The samples were read on a 7300 Real-Time PCR System
and were analyzed using SDS 1.4 software (Applied Bio-
systems). Additionally, 10 % of the samples were repeated
for quality control with complete congruence. Details are
presented in Table 1.
The research was carried out according to The Code
of Ethics of the World Medical Association (Declaration
of Helsinki). Informed consent was obtained from all
the examined patients. The study was approved by
the Ethics Committee of Silesian Medical Chamber,
Katowice, Poland.
Statistical analysis
Continuous variables are presented in terms of medians
and interquartile ranges, as they were not normally
distributed, and dichotomic variables are presented as
percentages. Genotype frequencies were determined by
their direct summing. Fisher’s exact test was used for de-
termination of consistency with Hardy–Weinberg equi-
librium (HWE). The Kruskal-Wallis test was used to test
for differences in the Gensini score according to the ge-
notypes of the studied polymorphisms. The Jonckheere-
Terpstra test was used to analyze possible trends in
Gensini score distribution. The associations between the
Gensini score and the polymorphisms were analyzed in
the whole cohort and in the subgroup of patients with-
out previous MI, using the following genetic models:
dominant, recessive and log-additive for EGF, IGF1,
PDGFB, TGFB1 and VEGFA, and dominant only for
FGF2 due to the low number of minor homozygotes.
These models were adjusted for clinical variables that
reached p values < 0.3 in the univariate regression
Table 1 Sequences of oligonucleotide probes used for polymorphism detection
Gene Polymorphism Nucleotide base Context sequence
FGF2 rs308395 C/G CTCTTCTATGGCCTACTTTCTACTG[C/G]
TATTTGTGTTACTCATGCTACCCAT
IGF1 rs35767 A/G GAATTTTTTCTTTTTTTTTTTTTCC[A/G]
CATGACTCTCAGGGGACTGACACAT
PDGFB rs2285094 T/C CAACCAATAGAGGGGCCAATAGAAC[T/C]
GCCCAGCTGAGCCCAGTCAACCCCC
TGFB1 rs1800470 A/G TAGCCACAGCAGCGGTAGCAGCAGC[A/G]
GCAGCAGCCGCAGCCCGGAGGGCGG
VEGFA rs699947 A/C GCCAGCTGTAGGCCAGACCCTGGCA[A/C]
GATCTGGGTGGATAATCAGACTGAC







Age (years) 64 (57 ÷ 70) 64 (58 ÷ 71)
Male sex, n (%) 224 (70.4) 171 (68.7)
Hypertension, n (%) 225 (70.8) 185 (74.3)
Heart failure, n (%) 72 (22.6) 53 (21.3)
Ejection fraction, n = 284 (89 %) 50 (45.0 ÷ 55.0) * 52 (48 ÷ 55) **
Atrial fibrillation, n (%) 46 (14.5) 40 (16.1)
Hypercholesterolemia, n (%) 150 (47.2) 117 (47.0)
Previous MI, n (%) 69 (21.7) –
Diabetes, n (%) 75 (23.6) 59 (23.7)
Diet/oral pharmacotherapy 45 (13.8) 38 (15.2)
Insulin 31 (9.7) 21 (8.4)
Creatinine (μmol/l) 79.8 (67.0 ÷ 89.9) 79.8 (66.5 ÷ 91.2)
*n = 284 (89.3 %) ** n = 221 (88.8 %); MI myocardial infarction
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analysis with the Gensini score as an outcome variable. This
cut off point was chosen as p values higher than 0.3 as selec-
tion criteria for adjusting for potential confounders are very
unlikely to improve model selection [8]. The associations of
the observed polymorphisms with the Gensini score after
adjustment were analyzed, and false discovery rate (FDR)
was calculated to account for multiple comparisons. The
number of patients enrolled is sufficient to detect, with a
power of 80 % the differences of Gensini score of 14.8 point
or greater assuming group sample sizes of 60 and 250 with
a standard deviation for both groups of 29.00 and at FDR=
0.05. Analyses were completed using NCSS (Number
Crunching Statistical Systems, Kaysville, Utah, USA) [9] soft-
ware, PASS (Power Analysis and Sample Size Software.
NCSS, LLC. Kaysville, Utah, USA) [10] and with the SNPas-
soc [11] and fdrtool package in the R environment [12, 13].
Results
The baseline clinical and demographic features of the study
population and the subgroup of patients without previous
MI are shown in Table 2. Patients’ genotypes were distrib-
uted in accordance with Hardy-Weinberg equilibrium, with
the exception of the rs4444903 polymorphism (Table 3).
Minor allele frequencies (MAFs) were similar to those re-
ported in other European populations, with the exception
of rs308395 in the FGF2 gene (Table 3). The associations
between FGF2, EGF, IGF1, PDGFB, TGFB1, and VEGFA
genotypes and the severity of CAD were investigated in the
whole cohort and in the subgroup of patients without pre-
vious MI (Table 4). In general, there were no differences
in the distribution of the Gensini score between the geno-
types of the analyzed polymorphisms in FGF2, EGF, IGF1,
PDFGB, and TGFB1 in the whole cohort and in the sub-
group of patients without previous MI. Similarly, after ad-
justment for clinical variables, there was no significant
association between the Gensini score and polymorphisms
in FGF2, EGF, IGF1, PDFGB, and TGFB1 under dominant,
recessive, and log-additive models (Additional file 1:
Table S1 and Additional file 2: Table S2).
For the VEGFA rs699947 SNP in the total patient group,
the median Gensini score was highest in patients with the
A/A genotype, lower in heterozygotes and lowest in
patients with the C/C genotype, with nominal p value for
trend = 0.04 and FDR = 0.07. This trend was significant for
adjusted threshold of significance after excluding patients
with previous MI (nominal p value = 0.013, FDR = 0.02).
After adjustment for clinical variables, the association be-
tween the VEGFA genotype and the Gensini score did not
meet the threshold of significance under the dominant
genetic model in patients without previous MI (nominal
p value = 0.04, FDR = 0.19) (Table 5).
Discussion
The pivotal roles of growth factors for endothelial cells
(ECs) and for SMCs have been recognized for over
20 years [14]. Growth factors such as bFGF, EGF, IGF-1,
PDGFB, TGF-β1 and VEGF-A play important roles in
VSMC and EC migration and proliferation, therefore
playing important roles in the pathogenesis of athero-
sclerosis. Polymorphisms selected for this study was
based on their functionality, which was understood as
influencing the level of gene expression or given growth
factor concentration (rs699947, rs4444903, rs180047) or
on the association of a given polymorphism with other
conditions (rs308395, rs699947, rs2285094) [15]. The
growth factors that we analyzed in this paper are both
acting on and secreted by ECs and VSMCs [16].
The role of bFGF in atherosclerosis is associated with its
mitogenic activity and its role in angiogenesis [17]. Add-
itionally, bFGF leads to a decrease in collagen [18–20] and
an increase in metalloproteinase (MMP) synthesis [21],
which may be one of the elements playing roles in
vulnerable plaque formation [22]. The localization of
rs308395 within the promoter region of the FGF2 gene
might explain its association with the FGF2 expression
level [23, 24]. In a Polish population, the C/C genotype
of rs308395 predicted a more aggressive course of non-
Hodgkin lymphoma [23]. In our paper, we did not find
any association between the severity of CAD and the
rs308395 polymorphism.
rs444903 in the EGF gene is the second of the ana-
lyzed polymorphisms. EGF influences the atherosclerotic
process because it affects the structure of atherosclerotic
lesions. Similarly to bFGF, EGF hampers the synthesis of
collagen fibers (type I and III) and increases MMP-9 and
MMP-1 gene expression levels [25]. Studies on primates
have shown that a high-cholesterol diet leads to activa-
tion of signal pathways associated with EGF [26]. Simi-
larly, as is the case for rs308395 in the FGF2 gene,
rs444903 is associated with the course of many cancers,
including lung cancer [27–29]. Despite the role of EGF
in atherosclerosis, our paper is the first to assess the
association of the known functional polymorphism
rs444903 with the severity of coronary atherosclerosis.
Nonetheless, we did not find any association between
analyzed polymorphism of EGF and Gensini score in
Table 3 MAFs of the analyzed SNPs in the analyzed cohort and
the European Union (EU) population




FGF2 rs308395 C/G 9.6 % 16 % 0.51
EGF rs4444903 A/G 42.0 % 39 % 0.006
IGF1 rs35767 A/G 16.0 % 16 % 0.06
PDGFB rs2285094 T/C 40.3 % 46 % 0.48
TGFB1 rs1800470 A/G 43.7 % 38 % 0.57
VEGFA rs699947 A/C 49.8 % 50 % 0.07
Osadnik et al. BMC Cardiovascular Disorders  (2016) 16:218 Page 4 of 8
patients with CAD who underwent their first coronary
angiography.
IGF-1 is also one of the EC and SMC growth regula-
tors. IGF-1 level has been inversely linked with athero-
sclerosis [30], and rs35767 polymorphisms in the IGF1
gene are associated with IGF-1 serum level [31]. Previ-
ously, we studied the relationship between IGF1 gene
polymorphisms and in-stent restenosis in patients
undergoing bare metal stent implantation, but we did
not find any association [32]. In contrast to polymor-
phisms in FGF2 and EGF, polymorphism rs35767 in the
IGF1 gene was studied in the context of atherosclerosis;
however, data are scarce [31]. Sesti G. et al. showed that
rs35767 was associated with not only IGF-1 level but
also intima-media thickness [31]. Another paper ana-
lyzed the association between polymorphisms in the
IGF1 gene and coronary arteriosclerosis. Similar to our
results, the authors did not observe any significant
correlation between rs35767 and the severity of CAD
(measured with the Gensini score) [33].
PDGF is a growth factor for cells of mesenchymal ori-
gin, including VSMCs, and supports their migration to
the lumens of vessels. PDFGB expression was also ele-
vated in patients with diabetes. With the exception of
one study in an African population, there have been no
analyses of PDGFB polymorphisms in the context of ath-
erosclerosis. There was, however, one study associating
rs2285094, which is located near the splice site, with






FGF2 Whole cohort 25 [16–48] 24 [14–59] 33.5 [22.8–45.5] 0.91 0.35*
Without previous MI 22 [15–44] 23.5 [14–56.8] 27 [20–34] 0.80 0.28*
A/A A/G G/G
EGF Whole cohort 24 [15–56.5] 26 [15.5–49.5] 22.3 [16–43.3] 0.79 0.34**
Without previous MI 22.5 [14–44] 25 [14–46] 20.5 [15.3–42.5] 0.68 0.34**
A/A A/G G/G
IGF1 Whole cohort 26 [20–44] 24.5 [14–44.3] 25 [16–56] 0.53 0.18*
Without previous MI 26.5 [21.9–44] 23 [12–43] 22 [14.5–46] 0.35 0.31*
C/C T/C T/T
PDGFB Whole cohort 22.8 [16–46] 25.5 [14–52] 25.5 [16–52.3] 0.78 0.25*
Without previous MI 22.3 [16.0–45.5] 22.5 [13–44.8] 22.0 [16.0–44] 0.75 0.32*
A/A A/G G/G
TGFB1 Whole cohort 24 [14–46] 25 [16–47] 26 [16–58] 0.5 0.14*
Without previous MI 24 [13.8–44.5] 22 [15.3–39.8] 22.5 [15.8–49.3] 0.96 0.45*
A/A A/C C/C
VEGFA Whole cohort 27 [17.5–46.3] 26 [16.0–56] 22 [14–47] 0.2 0.048**
Without previous MI 25 [17–44.5] 24.5 [14–46.4] 18 [12.0–43.3] 0.055 0.013**
Jonckhere Terpstra test for trend: *increasing, **decreasing
Table 5 Association of the VEGFA genotype with the Gensini score after adjustment for clinical variables
Gene /polymorphism Dominant Model*
(mean Gensini score ±
standard error)
P Recessive Model* (mean
Gensini score ± standard error)
P Log additive model* P
Genotypes Genotype Difference in Gensini score per minor allele (95 % CI)




37.9 ± 3.2 35.6 ± 1.9 0.57 37.9 ± 2.0 31.6 ± 2.7 0.22 −2.3 (−6.4 ÷ 1.9) 0.28
Patients without previous myocardial infarction
VEGFA
rs699947
26.4 ± 2.4 35.1 ± 2.1 0.04 31.4 ± 2.0 35.5 ± 3.3 0.41 3.8 (−0.51 ÷ 8.0) 0.09
*The models were adjusted for: age, sex, hypertension, atrial fibrillation, diabetes mellitus, previous myocardial infarction and creatinine
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higher incidence of sclerodermia [34]. This polymorph-
ism was also tested for possible associations with type 1
diabetes [35] and IgA nephropathy [36], though no rela-
tionship was found. We also did not detect any associ-
ation between rs2285094 and CAD burden.
The role of TGF-β1 in atherosclerosis has been con-
firmed and is well studied. In general, TGF-β1 stimulates
extracellular matrix production and inhibits SMC and
EC proliferation [5, 37, 38]. However, at levels exceeding
1–2 fg/cell, TGF-β1 may stimulate SMC, fibroblast and
chondrocyte proliferation [39]. TGF-β1 is also found in
blood serum, although studies aiming to compare
TGF-β1 levels and CAD severity yielded conflicting
results [5, 40–42]; additionally, TGF-β1 levels depend
on genetic factors [43–46]. Some researchers have associ-
ated the C alleles with higher TGF-β1 levels [44–46],
whereas other authors have postulated higher levels in T/
T homozygotes [44]. In our study, we did not observe any
relationship between rs1800470 in the gene coding for
TGF-β1 and the severity of coronary artery disease.
VEGF-A is a growth factor for EC and a factor influen-
cing migration of SMCs. The migration of SMCs over
the basal membrane to the intima is stimulated by
growth factors that influence the change of the SMC
phenotype from contractile to proliferative [14]. SMCs
that migrate to the intima proliferate and secrete extra-
cellular matrix proteins that form a fibrous cap on the
atherosclerotic lesion. Enlargement of atherosclerotic
lesions leads to local hypoxia, which leads to increased
VEGF-A synthesis and neovascularization of the athero-
sclerotic lesion. Studies on animal models have shown
that VEGF-A injection caused increases in the athero-
sclerotic lesion area and influenced the lipid profile and
lipoprotein lipase concentration [47]. VEGF-A levels are
also genetically determined; rs699947 is one of the poly-
morphisms that significantly influences its serum con-
centration [48, 49]. This polymorphism was linked to
increased risk of various neoplasms [50], including lung
cancer [51]. In our paper, we have shown trend toward
association between rs699947 and the severity of CAD
in patients without previous MI.
Similar results were obtained by Howell et al., who
showed a significant correlation between rs699947 and
the severity of CAD, but only among patients with stable
CAD and without previous MI [4]. Howell et al. ex-
plained this finding by the fact that the influence of
rs699947 on atherosclerosis is modest and can be veiled
by stronger environmental or genetic factors leading to
MI. While agreeing with the interpretation of Howell et
al., we are also of the opinion that different results in pa-
tients with previous MI and in patients with stable CAD
without previous MI might stem from different patho-
physiologies leading to the development of stable and
vulnerable plaques [16].
Conclusions
We were unable to find strong association between ana-
lyzed polymorphisms in growth factors and the severity
of coronary artery disease, although there was a trend
toward association between rs699947 and the severity of
CAD in patients without previous MI.
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